CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $49.00 by Analysts at Stifel Nicolaus

CRISPR Therapeutics (NASDAQ:CRSP) had its price objective decreased by Stifel Nicolaus from $53.00 to $49.00 in a research note released on Thursday,Benzinga reports. Stifel Nicolaus currently has a hold rating on the stock.

A number of other research analysts also recently commented on CRSP. Chardan Capital dropped their price target on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a research report on Thursday. HC Wainwright restated a “buy” rating and set a $65.00 price target on shares of CRISPR Therapeutics in a report on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. Finally, Royal Bank of Canada reduced their price objective on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research report on Wednesday. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $74.05.

CRISPR Therapeutics Price Performance

Shares of CRSP opened at $43.49 on Thursday. The stock has a market capitalization of $3.71 billion, a price-to-earnings ratio of -15.37 and a beta of 1.67. CRISPR Therapeutics has a 1 year low of $36.52 and a 1 year high of $91.10. The business’s 50 day simple moving average is $42.06 and its 200-day simple moving average is $46.25.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. On average, sell-side analysts expect that CRISPR Therapeutics will post -5.08 earnings per share for the current year.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the sale, the chief executive officer now owns 181,540 shares in the company, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Large investors have recently bought and sold shares of the business. Boston Family Office LLC increased its holdings in shares of CRISPR Therapeutics by 2.2% in the 3rd quarter. Boston Family Office LLC now owns 9,763 shares of the company’s stock valued at $459,000 after acquiring an additional 213 shares during the period. Bedell Frazier Investment Counselling LLC raised its holdings in CRISPR Therapeutics by 0.8% in the third quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company’s stock worth $1,238,000 after purchasing an additional 218 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of CRISPR Therapeutics by 1.9% during the third quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company’s stock valued at $586,000 after buying an additional 231 shares during the last quarter. Intellectus Partners LLC boosted its holdings in shares of CRISPR Therapeutics by 3.6% in the 4th quarter. Intellectus Partners LLC now owns 7,131 shares of the company’s stock valued at $281,000 after buying an additional 250 shares in the last quarter. Finally, Farrow Financial Inc. grew its position in shares of CRISPR Therapeutics by 1.4% in the 4th quarter. Farrow Financial Inc. now owns 20,097 shares of the company’s stock worth $777,000 after buying an additional 270 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.